

## **Oxidative stress induced dysregulation of excitation-contraction coupling contributes to muscle weakness**

Rizwan Qaisar<sup>1</sup>, Shylesh Bhaskaran<sup>1</sup>, Pavithra Premkumar<sup>1</sup>, Rojina Ranjit<sup>1</sup>, Kavithalakshmi Satara Natarajan<sup>1</sup>, Bumsoo Ahn<sup>1</sup>, Kaitlyn Riddle<sup>1</sup>, Dennis R Clafin<sup>2,3</sup>, Arlan Richardson<sup>5,3,6</sup> Susan V. Brooks<sup>4</sup>, Holly Van Remmen<sup>1,5</sup>

<sup>1</sup> Aging and Metabolism Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.

<sup>2</sup> Department of Surgery, Section of Plastic Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA

<sup>3</sup> Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, USA

<sup>4</sup> Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan

<sup>5</sup> Oklahoma City VA Medical Center, Oklahoma City, OK 73104, USA.


<sup>6</sup> Department of Geriatric Medicine and the Reynolds Oklahoma Center of Aging, Oklahoma University Health Science Center, Oklahoma City, OK, USA

### **Corresponding author:**

Holly Van Remmen, Ph. D.  
Aging and Metabolism Research Program  
Oklahoma Medical Research Foundation  
825 NE 13<sup>th</sup> Street  
Oklahoma City, OK 73104  
Phone: 405-271-2520  
Fax: 271-3470  
Email: Holly-VanRemmen@omrf.org


**Supplementary Fig 1. Muscle fatigue**

Time course of contractile force decline in EDL muscles during 400 seconds of fatiguing stimulations. Values are expressed as Mean  $\pm$  SEM (n = 8-12 per group). ; One-way ANOVA. \*  $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\*  $P \leq 0.001$ , \*\*\*\*  $P \leq 0.0001$  ANOVA.



**Supplementary Fig 2. Expressions of genes associated with muscle quantity and quality**

mRNA expression of genes associated with muscle functional and structural phenotypes in the gastrocnemius muscles of young and old WT and Sod 1<sup>-/-</sup> mice. Values are expressed as Mean ± SEM (n = 8-12 per group). One-way ANOVA. \* P ≤ 0.05,



**Supplementary Table 1. Muscle weights**

Absolute muscle weights and the muscle weights normalized to body weights from the young and old WT and *Sod 1<sup>-/-</sup>* mice. Values are expressed as Mean  $\pm$  SEM (n = 8-12 per group). \*  $P < 0.05$  vs. Young WT, €  $P < 0.05$  vs. Old WT; 1-way ANOVA.

	Young WT	Old WT	<i>Sod 1<sup>-/-</sup></i>
<b><u>Muscle weights (g)</u></b>			
Quadriceps	0.44 $\pm$ 0.01	0.35 $\pm$ 0.01*	0.32 $\pm$ 0.14*
Tibialis Anterior	0.15 $\pm$ 0.01	0.10 $\pm$ 0.01*	0.10 $\pm$ 0.01*
EDL	0.03 $\pm$ 0.003	0.02 $\pm$ 0.002*	0.02 $\pm$ 0.003*
<b><u>Muscle Weights / Body Weights (%)</u></b>			
Quadriceps	1.20 $\pm$ 0.048	0.92 $\pm$ 0.031*	1.14 $\pm$ 0.034€
Tibialis Anterior	0.40 $\pm$ 0.02	0.29 $\pm$ 0.03*	0.35 $\pm$ 0.015
EDL	0.08 $\pm$ 0.007	0.05 $\pm$ 0.004*	0.08 $\pm$ 0.008€

**Supplementary Table 2. Primers sequences for RT-PCR**

<b>Gene</b>		<b>Primer Sequence</b>
SLN	F R	GAGGTGGAGAGACTGAGGTCCTTGG GAAGCTCGGGGCACACAGCAG
GADD45a	F R	AGACCGAAAGGATGGACACG GTACACGCCGACCGTAATG
mCpne2	F R	CATCCCCTTGGGTTCTCAGTG GTTGACGGCTGTTTCTGTTCT
SERCA2	F R	GAGAACGCTCACACAAAGACC CAATTCGTTGGAGCCCCAT
JPH1	F R	CAGCGGCAACACCTACCAG GTAGCGCCCCTTGAACCAT
Sypl1	F R	AAAGGCCTGTCCGATGTGAAG TCCCTCAGTTCCTTGCATGTG
LRP4	F R	TCTGCGCACACGGAATAGC GCGCTCACCGCACATGT
SRL	F R	GCAGAAGTGCAAGAGGGGAAGT TCTAGCTCTGTGGATTGGTGA
AChR-d	F R	CATCGAGTGGATCATCATTGAC CGGCGGATGATAAGGTAGAA
MyHC-2a	F R	ATGAGCTCCGACGCCGAG TCTGTTAGCATGAACTGGTAGGCG
JSPR1	F R	AGAACGTGGAGGGTCCATCTC TCCCCTTTACTTGGCTTCTCTTT
AChR- $\alpha$	F R	ACCTGGACCTATGACGGCTCT AGTTACTCAGGTCGGGCTGGT
MyoZ	F R	TGAACCAGTCCCTTCGCTG ATGGCCTGCAAACCTTTCTGAT
MyHC-1	F R	CCTTGGCACCAATGTCCCGGCTC GAAGCGCAATGCAGAGTCGGTG
SERCA1	F R	TGTTTGTCTATTTTCGGGGTG AATCCGCACAAGCAGGTCTTC
MyHC-2x	F R	AAGGAGCAGGACACCAGCGCCCA ATCTCTTTGGTCACTTTCTGCT
MRF4	F R	TGCTAAGGAAGGAGGAGCAA CCTGCTGGGTGAAGAATGTT
MUSK	F R	TCCTGCGTGCTCCTGAATC TGCAGCGTAGGGTTACAAAGG
CSQ	F R	CTGGCACTGCTGTTTGTACTG GGGGGCTCATGGTAGAGGAG
HRC	F R	GGAACACGACCCTTGTGTG GGACTCGTTTTCTCTCCACG
Sypl2	F R	CGCACCTCGGACAAGTCTC CCCGAAGGCGAAAATAGC
Cav1.1	F R	GTTACATGAGCTGGATCACACAG ATGAGCATTTTCGATGGTGAAG

MusA	F R	TCGTGGAATGGTAATCTTGC CCTCCCGTTTCTCTATCACG
Rapsyn	F R	GGGACTGGAGGATGCTGACTT TGCGCGCCAGGTTCA
AChR-e	F R	GATTGGCATTGACTGGCACG CCACTCCAACTGCCCATC
Col1a1	F R	CAGTCGATTCACCTACAGCACG GGGATGGAGGGAGTTTACACG
Trd	F R	AGAAGACAGCAACTCACAAAGAG GGTGGTGGCATAACTGGGC
MyHC-2b	F R	GTGATTTCTCCTGTCACCTCTC GGAGGACCGCAAGAACGTGCTGA
PLN	F R	ATGACGACGATTCAAATCTCTTGG TGGGTTTGCAAAGTTAGGCATAA

Note: SLN: Sarcolipin; GADD45a: Growth arrest and DNA-damage-inducible protein 45a; mCpne2: Copine 2; SERCA2: Sarcoplasmic reticulum calcium ATPase 2; JPH1: Junctophilin 1; Sypl1: Synaptophysin like 1; LRP4: LDL receptor related protein 4; SRL: Sarcalumenin; AChR-d: Acetylcholine receptor delta; MyHC-2a: Myosin heavy chain type 2a; JSRP1: Junctional sarcoplasmic reticulum protein 1; AChR- $\alpha$ : Acetylcholine receptor alpha; MyoZ: Myozenin; MyHC-1: Myosin heavy chain type 1; SERCA1: Sarcoplasmic reticulum calcium ATPase 1; MyHC-2x: Myosin heavy chain type 2x; MRF4: Myogenic regulatory factor 4; MUSK: Muscle associated receptor tyrosine kinase; CSQ: Calsequestrin; HRC: Histidine-rich calcium binding protein; Sypl2: Synaptophysin like 2; Cav1.1: Calcium channel, voltage dependent, L type, alpha 1S subunit; AChR-e: Acetylcholine receptor epsilon; Col1a1: Collagen type 1 alpha 1; trd: triadin; MyHC-2b: Myosin heavy chain type 2b; PLN: Phospholamban